Liquid Liver Fractions: An Encyclopedic Reference
1. Identity, Nomenclature, and Natural Source
Liquid Liver Fractions is a dietary supplement ingredient derived from the enzymatic or acid hydrolysis of animal liver tissue. The term encompasses a family of closely related preparations variously labeled in the scientific and commercial literature as liver hydrolysate, liver extract, hydrolysed liver powder, aqueous liver extract, liver substance, liver concentrate, or liver peptide extract. The NIH Dietary Supplement Label Database (DSLD) formally lists "Liquid Liver Fractions" as an ingredient and associates it with a wide range of synonymous trade names, including Argentine beef liver, beef liver powder, beef liver freeze-dried, predigested liver concentrate, and others.
Liver hydrolysate, often referred to as hydrolysed liver powder or liver peptide extract, is produced by enzymatic breakdown of fresh animal liver — typically bovine or porcine — into smaller peptides and amino acids. Liver hydrolysate is typically derived from the livers of cattle (beef liver), pigs (pork liver), fish (fish liver), or poultry (such as chicken or duck liver). Among commercial preparations targeted at dietary supplements, bovine (beef) liver sourced from Argentina is frequently featured, as noted on labels registered with the NIH DSLD.
Different sources may result in variations in amino acid composition, bioactive compounds, and overall nutritional value. For example, beef liver hydrolysate is often rich in B vitamins and iron, fish liver hydrolysate may contain higher levels of unsaturated fatty acids and vitamin A, while poultry liver hydrolysate may have distinct protein and enzyme activity characteristics.
Common Forms and Preparations
This process enhances bioavailability compared to whole desiccated liver, resulting in a fine powder rich in low-molecular-weight peptides (usually <3 kDa), branched-chain amino acids, taurine, anserine, and essential micronutrients like heme iron, B vitamins, and copper. Commercially, it is manufactured through controlled proteolysis using food-grade enzymes (e.g., papain or alcalase), followed by filtration, concentration, and spray-drying to achieve consistent peptide content and purity.
In terms of physical appearance, liver hydrolysate is commonly found as a light yellow to brownish-yellow powder, with hygroscopic properties and good water solubility. It is incorporated into capsules, tablets, and liquid tonics. Due to its rich nutritional profile, it is widely used in dietary supplements, pharmaceutical formulations, and cell culture media.
Specific product labels on the NIH DSLD describe preparations such as "predigested beef liver concentrate from animals raised in Argentina without the use of chemical sprays, pesticides or antibiotics," constituting predigested and concentrated beef liver fractions. These preparations are distinguished from whole desiccated liver in that enzymatic predigestion is intended to break larger proteins into smaller, more readily absorbed peptide units before consumption.
2. Traditional and Historical Use
The use of animal liver as a food medicine predates recorded history in many cultures, with liver tissue being consumed across ancient civilizations for its perceived restorative properties. The more targeted use of concentrated or extracted liver preparations as a therapeutic agent, however, is predominantly a 19th- and 20th-century development rooted in Western and East Asian medical traditions.
Pernicious Anemia and Early Pharmaceutical Use (19th–20th Century, Western Medicine)
One of the most historically significant applications of liver-derived preparations was in the treatment of pernicious anemia. In 1926, George Minot and William Murphy demonstrated that consuming large amounts of raw liver could reverse pernicious anemia — a discovery for which they shared the 1934 Nobel Prize in Physiology or Medicine. This finding drove the development of injectable and oral liver extracts as medicinal products in the early 20th century. The active factor was later identified as vitamin B12 (cyanocobalamin), but for decades before this identification, crude liver extracts were the primary treatment for megaloblastic and pernicious anemia.
Traditional Use in Japan and Asia
In Japan, certain liver-derived ingredients have historical use in quasi-drug categories, though such classification does not apply internationally. Liver hydrolysate preparations have been used in Japanese clinical and near-pharmaceutical contexts for liver support and fatigue management for several decades, occupying a regulated quasi-drug (第2類医薬品) space distinct from standard dietary supplements. International acceptance varies, with use in functional foods and supplements in regions like Asia.
Chronic Fatigue and General Tonic Use
It appears in historic research that the extract has been used for centuries for several medical purposes including treatment of chronic fatigue syndrome and severe allergic reactions. An injectable bovine liver extract formulation combined with folic acid and cyanocobalamin — known commercially as LEFAC (liver extract-folic acid-cyanocobalamin) — was particularly advocated in Southern California during the 1980s as a treatment for what was then described as chronic fatigue syndrome. A frequently advocated treatment in Southern California was an injectable solution of bovine liver extract containing folic acid and cyanocobalamin (LEFAC).
General Tonic and Liver Support
Liver hydrolysate has found application in tonics for oral use, which work as a booster to regain energy and help to restore liver and body function. The use of liver-based tonics for general vitality, convalescence, and support during infectious illness has long been part of both European and East Asian health traditions, driven by the nutritional density of the organ.
3. Key Constituents and Active Compounds
Liquid liver fractions are nutritionally complex materials, combining macro- and micronutrient fractions with bioactive peptides generated during enzymatic processing.
Micronutrients
- Heme Iron: Liver fractions are characterized as a superior source of heme iron and other blood-building nutrients. Liver contains a source of iron bound to hemoglobin (heme iron) of which up to 33% is absorbed compared to non-heme iron, which can have as little as 2% absorption.
- Vitamin B12 and Folate: Liver extract contains vitamin B12, folic acid, and iron. These are present naturally in liver tissue and are often further supplemented in finished products.
- Copper: The product is rich in essential micronutrients like heme iron, B vitamins, and copper. Liver is one of the richest dietary sources of copper.
- Vitamin A (Retinol): Animal liver is a highly concentrated source of preformed vitamin A (retinol). Beef liver and its concentrated derivatives contain significant quantities that must be accounted for during supplementation.
Bioactive Peptides and Amino Acids
Liquid liver fractions are derived primarily from fresh bovine or porcine liver through controlled hydrolysis, yielding small-molecular-weight peptides, free amino acids, and bioactive compounds such as anserine, branched-chain amino acids (BCAAs), and taurine.
The present study was conducted to identify anti-fatigue peptides in porcine liver hydrolysate (LH) and to evaluate their effects. Peptides in LH were fractionated into hydrophilic and hydrophobic fractions and further into peptides with amino groups (Pep-NH2) and pyroglutamyl peptide fractions (pE). Specific dipeptides identified in porcine liver hydrolysate include Asp-Val, Asp-Leu, and Asp-Phe. In particular, Asp-Leu (Lβ), Asp-Phe (Dα), and Asp-Phe (Lα) exerted anti-fatigue effects at a low concentration (0.03 mg/kg). It was found that Asp-Phe (Lα), but not other dipeptides, activated adenosine monophosphate-activated protein kinase (AMPK) in the liver.
Comparative Nutritional Composition by Species
Liver hydrolysate is typically derived from the livers of cattle, pigs, fish, or poultry, and different sources may result in variations in amino acid composition, bioactive compounds, and overall nutritional value. Beef liver hydrolysate is often rich in B vitamins and iron, fish liver hydrolysate may contain higher levels of unsaturated fatty acids and vitamin A, while poultry liver hydrolysate may have distinct protein and enzyme activity characteristics.
4. Established and Proposed Mechanisms of Action
Heme Iron Absorption
The primary and most scientifically substantiated mechanism attributed to liquid liver fractions is the delivery of highly bioavailable heme iron. Iron absorption involves heme iron from animal-based foods and non-heme iron from plant-based foods and supplements. Heme iron, present in meats, poultry, and seafood, is more readily absorbed and has a higher bioavailability than non-heme iron. Once consumed, heme iron is released from ingested proteins in the stomach's acidic environment and the small intestine.
About 25% of dietary heme iron is absorbed, while 17% or less of dietary non-heme iron is absorbed. A 2025 review published in Nutrients (MDPI) further quantified this difference: heme iron is 200–400% more bioavailable than non-heme forms of iron. Dietary heme iron is absorbed through the active transport pathways catalyzed by heme oxygenase in the intestinal enterocyte.
Heme iron has higher bioavailability than nonheme iron, and other dietary components have less effect on the bioavailability of heme than nonheme iron. This is clinically relevant because the absorption of non-heme iron from standard iron salts is significantly modulated by dietary factors such as phytates, calcium, and polyphenols, whereas heme iron largely bypasses these inhibitory interactions. Unlike non-heme iron salts, which cause unpleasant gastrointestinal disturbances at high doses, heme iron achieves optimal absorption at lower doses and is not associated with unabsorbed iron toxicity.
AMPK Activation and Energy Metabolism
The aim of preclinical investigations has been to investigate the effect of liver hydrolysate on alterations in locomotor activity and energy metabolism such as 5′-AMP-activated protein kinase (AMPK), glycogen content, and blood lactic acid, after forced walking. Findings indicate that LH produced an anti-fatigue effect and that this effect appears to involve the efficient glycogen utilization through activation of AMPK.
Treatment reversed the forced walking-induced increase in blood lactate levels in mice and increased phosphorylated AMP-activated protein kinase (p-AMPK) in the soleus muscle, suggesting that the anti-fatigue effect involves AMPK activation in the soleus muscle through reduced blood lactate.
Hepatoprotection: Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Mechanisms
Results from animal studies showed that a chicken-liver hydrolysate-based supplement (GBHP01™) could reduce enlarged liver size, lipid accumulation/steatosis scores, and higher serum AST, ALT, γ-GT, triglyceride, and cholesterol levels induced by an alcoholic liquid diet. The supplement reduced liver inflammation and apoptosis via decreasing TBARS, interleukin-6, interleukin-1β, and tumor necrosis factor-α levels, increasing reduced GSH/TEAC levels and activities of SOD, CAT and GPx, as well as downregulating CYP2E1, BAX/BCL2, Cleaved CASPASE-9/Total CASPASE-9 and Active CASPASE-3/Pro-CASPASE-3.
Additionally, the peptide mixture contributes to antioxidant activity by scavenging free radicals and supporting endogenous enzymes. It has been reported that chicken liver hydrolysates (CLHs) could decrease the proinflammatory cytokine secretions, i.e., IL-1β, IL-6, and TNF-α in alcoholic damaged livers or high-fat diet fed livers.
5. Scientific Evidence by Area of Use
5.1 Iron Status and Anemia
Area Summary: The heme iron content of liver fractions constitutes the most robustly supported mechanism, though clinical trials specifically using liquid liver fractions as the tested intervention are sparse. The broader evidence base for heme iron superiority over non-heme iron in supplementation is well-documented.
A 2024 systematic review and meta-analysis published in PMC, analyzing 13 randomized controlled trials comparing heme iron (HI) with non-heme iron (NHI), concluded that bioavailability studies and observational evidence suggest that heme iron (HI) may have greater impact on iron status indicators compared with non-heme iron (NHI). Heme iron contributes about 10% to 15% of total dietary iron intake in Western populations, but its higher bioavailability results in it being approximately 40% of the total iron absorbed.
Evidence Strength: The superiority of heme iron bioavailability over non-heme iron is well-established in the nutritional science literature and acknowledged by the NIH Office of Dietary Supplements. However, direct randomized controlled trials specifically using concentrated liquid liver fractions in supplement form as the intervention for clinically diagnosed iron deficiency anemia are not presently available in peer-reviewed literature. The extrapolation from general heme iron science to supplemental liver fraction products remains an indirect inference.
5.2 Anti-Fatigue and Physical Recovery
Area Summary: Preclinical (animal model) evidence suggests anti-fatigue effects through AMPK-mediated glycogen utilization, but human clinical evidence is absent or negative.
A study published in the Journal of Pharmacological Sciences (Kanazawa University, Japan) used adult male ddY mice to examine the effect of liver hydrolysate on locomotor activity following forced walking. Two administrations of LH (30 or 100 mg/kg) significantly increased the locomotor activity, while a single administration either before or after forced walking did not show any specific effect. Administering LH twice activated AMPK in the liver and soleus muscle. In contrast, administering LH twice increased muscle glycogen and decreased blood lactic acid. These findings indicate that LH produced an anti-fatigue effect and that this effect appears to involve the efficient glycogen utilization through activation of AMPK.
Research identifying specific bioactive dipeptides from porcine liver hydrolysate further characterized the mechanistic basis: the anti-fatigue effects of specific dipeptides — including Asp-Val, Asp-Leu, and Asp-Phe — which appeared in blood after oral administration of LH, were examined. In particular, Asp-Leu (Lβ), Asp-Phe (Dα), and Asp-Phe (Lα) exerted anti-fatigue effects at a low concentration (0.03 mg/kg).
The sole identified human clinical trial of injectable liver extract for fatigue — the landmark Kaslow et al. (1989) study — found no benefit. A frequently advocated treatment in Southern California was an injectable solution of bovine liver extract containing folic acid and cyanocobalamin (LEFAC). Kaslow et al. conducted a double-blind, placebo-controlled, crossover trial of intramuscular LEFAC in 15 patients who met the Centers for Disease Control criteria for chronic fatigue syndrome. Although patients responded to placebo and LEFAC by several criteria of functional status, no significant difference was apparent between response to placebo and active treatment. This trial was published in Archives of Internal Medicine (1989; 149:2501–2503) and remains the only identified placebo-controlled human trial of a liver extract formulation specifically for fatigue.
Evidence Strength: Anti-fatigue effects are supported only by animal model data. The one available human clinical trial (n=15, injectable formulation, 1989) found no significant benefit over placebo. No oral supplementation trials in humans have been identified. Overall evidence for anti-fatigue use in humans is currently insufficient and negative where tested.
5.3 Hepatoprotection and Liver Function
Area Summary: Animal (preclinical) evidence from multiple published studies supports hepatoprotective effects of chicken and bovine liver hydrolysate preparations under specific toxic insults (alcohol, thioacetamide). Human clinical evidence is limited.
A study published in Environmental Toxicology (2024; 39(3):1759–1768) investigated hepatoprotection of a chicken-liver hydrolysate-based supplement (GBHP01™) against chronic alcohol consumption in mice. Results showed that GBHP01™ could reduce enlarged liver size, lipid accumulation/steatosis scores, and higher serum AST, ALT, γ-GT, triglyceride, and cholesterol levels induced by an alcoholic liquid diet.
A separate study published in Antioxidants (2023; 12(2):493) examined liver fibrogenesis. This study investigated if a CLH-based supplement (GBHP01™) can ameliorate liver fibrogenesis induced by thioacetamide (TAA) treatment. Results showed that the TAA treatment caused lower body weight gains and enlarged livers, as well as higher serum ALT, AST, and ALP levels (p < 0.05). This liver inflammatory and fibrotic evidence was ameliorated (p < 0.05) by supplementing with GBHP01™; this partially resulted from its antioxidant abilities, including decreased TBARS values but increased TEAC levels, reduced GSH contents and catalase/GPx activities.
A small double-blind clinical study of a total liver extract formulation in patients with hepatic dysfunction was conducted by Preziosi et al. in 1975 (Int. J. Clin. Pharmacol. Biopharm.; 11(3):210-215). Separately, Ebinuma et al. (2004) examined the liver extract preparation "Adelavin-9" as an adjunct to interferon-β treatment for chronic hepatitis C (Hepatogastroenterology; 51(58):1109-1114); however, full details of both studies are accessible only through their original journal publications, and their sample sizes and methodological rigor are not sufficient for strong evidentiary conclusions.
People take liver extract by mouth or by injection for various conditions, especially for liver health or as a source of iron and vitamin B12, but there is no good scientific evidence to support these uses. This assessment from WebMD's Natural Medicines database reflects the current state of the human clinical literature.
Evidence Strength: Hepatoprotective effects are demonstrated in animal studies with consistent mechanistic findings. Human clinical evidence is very limited (small, older trials with methodological limitations). The overall human evidence base is insufficient to draw firm conclusions about efficacy for liver disease in humans.
5.4 Cognitive and Neurological Effects
Liver hydrolysate has been reported to have an antidepressant effect in an animal model of depression via enhancement of hippocampal neurogenesis through the AMPK/BDNF pathway. This observation, from preclinical Japanese research, has not been translated into human clinical trials as of current literature availability.
Evidence Strength: Animal model only. No human clinical trials identified.
6. Body Systems and Health Areas Associated with Liquid Liver Fractions
- Hematopoietic system: Heme iron delivery for red blood cell production; historical application in iron deficiency anemia and pernicious anemia (the latter via vitamin B12 content).
- Hepatic system: Preclinical hepatoprotective effects against alcoholic liver disease, steatosis, and liver fibrogenesis; historical and contemporary use as a liver tonic.
- Musculoskeletal and metabolic: Anti-fatigue mechanisms via AMPK-mediated glycogen utilization and lactate reduction in animal models; marketed for endurance and athletic recovery.
- Neurological: Preclinical antidepressant and neurogenic effects via AMPK/BDNF pathways in animal models; no human data.
- Gastrointestinal: The liver performs many essential functions related to digestion and to the gastrointestinal tract, including synthesis of bile. Liver hydrolysate is manufactured from livers of healthy animals by a special lenient process preserving all essential qualities of liver, making it suitable for application in oral supplements aiming to enhance liver function and facilitate digestion.
7. Dosage Forms and Reported Dosages
Liquid liver fractions are available in multiple physical forms:
- Capsules and tablets: The most common supplement form. A commercially registered product on the NIH DSLD specifies a dose of 2 capsules, twice daily as the recommended regimen.
- Liquid tonics: Liver hydrolysate has found application in tonics for oral use.
- Injectable solution: The historical LEFAC preparation used in the Kaslow et al. (1989) trial was administered as intramuscular injections in 15 patients in the clinical trial setting.
One NIH DSLD-registered product label discloses that each serving of Liver Fractions (from predigested liver concentrate, containing natural heme iron) provides 1,300 mg, combined with folate (340 mcg DFE as (6S)-5-Methyltetrahydrofolic acid), vitamin B12 (1,000 mcg as methylcobalamin), and iron (5 mg as Ferrochel® ferrous bisglycinate chelate).
In the anti-fatigue animal studies, two administrations of LH (30 or 100 mg/kg) significantly increased the locomotor activity in forced-walking mouse models. These animal doses cannot be directly extrapolated to human equivalent doses without formal conversion and clinical validation.
In the hepatoprotective animal studies using GBHP01™ chicken-liver hydrolysate, the supplement was administered in the context of a controlled liquid diet over a defined treatment period; specific human-equivalent oral doses have not been established through controlled clinical trials.
8. Safety Considerations and Interactions
Vitamin A (Retinol) Toxicity
Animal liver is among the most concentrated dietary sources of preformed vitamin A (retinol). Beef liver is one of the richest dietary sources of preformed vitamin A (retinol). In supplement form, even a few grams of dried powder can exceed the tolerable upper intake level, especially if combined with other fortified foods or multivitamins. Risks such as vitamin A toxicity, potential contaminants, or heavy metal accumulation are not well understood. The World Health Organization warns that chronic intake of high-retinol animal products can contribute to hypervitaminosis A, particularly in populations already consuming fortified foods or supplements.
Heavy Metal and Environmental Contaminant Accumulation
Because the liver is the primary detoxification and metabolic organ in vertebrates, it can accumulate environmental contaminants from the animal's exposure. As a filtering organ, the liver can accumulate heavy metals, pesticides, and environmental toxins from the animal's diet and environment. While high-quality sourcing can reduce this risk, not all brands test for contaminants.
A peer-reviewed study in Nutrients analyzing heavy metal content in Italian heavy pig tissues found that As, Cd, Cu, Fe, Hg, Pb, U, and Zn showed significantly higher concentrations in livers compared to muscles (p ≤ 0.01), with Cd and Cu being 60- and 9-fold more concentrated in the hepatic tissue. Despite this, concentrations of all TMMs were found to be very low in all the samples to the point that the resulting estimated dietary intakes did not suggest any food safety concern. However, the same study noted that in the calculation of the worst-case exposure scenario, the children's estimated intake of Cd, Fe, and Zn through the sole consumption of pig liver contributed to more than 23, 38, and 39% of the tolerable weekly intakes of these elements. These findings alert about the probability of exceeding the toxicological guidance values of Cd, Fe, and Zn through the whole diet, suggesting long-term negative health effects for the younger population.
Iron Overload
Because liver fractions deliver highly bioavailable heme iron, supplementation in individuals with normal or elevated iron stores raises concerns about iron overload. Conditions such as hereditary hemochromatosis, where iron accumulates pathologically, may be worsened by additional high-bioavailability iron supplementation. Iron overload in the liver can aggravate ethanol-elicited liver damage by potentiating oxidative stress via Fenton reaction, promoting activation of Kupffer cells and hepatic stellate cells, and inducing ferroptosis. This mechanism underscores the potential for harm from excess iron in the context of liver disease.
Long-Term Safety Data
There are no peer-reviewed studies examining the long-term safety of taking concentrated beef liver in capsule form daily. The absence of long-term safety trials is a significant evidential gap for this supplement category.
FDA and Regulatory Status
In the United States, liquid liver fractions are regulated as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA) of 1994 and do not require pre-market approval for safety or efficacy. The FDA has previously communicated concerns to manufacturers regarding the safety of specific bovine tissues in dietary supplements in the context of bovine spongiform encephalopathy (BSE/prion disease) risk, particularly for neural and spinal tissues; liver, while an organ meat, is among the tissues that may be subject to sourcing and processing restrictions depending on country of origin and the FDA's import and safety guidance for bovine-derived dietary supplement ingredients. Products are produced under GMP and meet standards for purity and labeling in supplements emphasizing nutritional support.
Potential Drug Interactions
No controlled human pharmacokinetic drug interaction studies specific to liquid liver fractions have been identified in the literature. Because these preparations contain significant amounts of vitamin B12, folate, and iron, theoretical interactions exist with:
- Medications that affect iron absorption (e.g., proton pump inhibitors, tetracycline antibiotics, levodopa — concomitant iron may reduce absorption of these drugs)
- Folate-sensitive medications (e.g., methotrexate, whose activity may be influenced by high-dose folate co-administration)
- Anticoagulants (vitamin K content of liver tissue, though typically processed out in hydrolysates, should be considered)
These are pharmacological inferences based on the known constituent profile; no direct interaction trials have been conducted.
Pregnancy and Special Populations
The NIH DSLD product label for one registered liver fractions supplement notes that pregnant or nursing women should consult a healthcare practitioner before using. The high preformed vitamin A content of liver-derived supplements is of specific concern in pregnancy, as excess retinol is a known human teratogen at high doses.
9. Evidence Summary and Overall Assessment
Liquid liver fractions occupy a distinctive position in the dietary supplement landscape: they deliver a matrix of genuinely bioactive and nutritionally substantiated constituents — particularly heme iron, vitamin B12, folate, and bioactive peptides — but the clinical evidence base for most of the health claims made in the marketplace is weak, indirect, or absent in humans.
- Heme iron bioavailability: Well-established in nutritional science; strongest mechanistic and indirect clinical support of any constituent in this product class.
- Anti-fatigue effects: Mechanistically plausible based on AMPK/glycogen/lactate preclinical data; the one controlled human trial (Kaslow, 1989) was negative.
- Hepatoprotective effects: Consistent across multiple animal studies; human evidence is sparse, older, and methodologically limited.
- Cognitive and neurological effects: Animal model only; no human data.
- Long-term safety: No peer-reviewed long-term safety studies; vitamin A toxicity and heavy metal accumulation are the most substantiated concerns. Sourcing integrity (pasture-raised, antibiotic-free, contaminant-tested) is a relevant quality differentiator.
From "testosterone boosting" to "immune system fortification," most marketed benefits are based on historical use or nutrient assumptions, not human clinical trials. The Cochrane Database of Systematic Reviews consistently finds that without direct human trials, claims based on food composition alone cannot be considered evidence-based.
References
- NIH Office of Dietary Supplements – Dietary Supplement Label Database: Liquid Liver Fractions (Ingredient)
- NIH DSLD: Liver Fractions Product Label (EuroPharma, Inc.)
- ErgoYoung: Liver Hydrolysate for Premium Wellness Formulations (January 2026)
- Nutri Avenue: Liver Hydrolysate Ingredient Profile
- Wu et al. (2024). A functional chicken-liver hydrolysate-based supplement ameliorates alcohol liver disease via regulation of antioxidation, anti-inflammation, and antiapoptosis. Environmental Toxicology, 39(3):1759–1768. PubMed ID: 38054388
- Wu et al. (2023). Hepatic-Modulatory Effects of Chicken Liver Hydrolysate-Based Supplement on Autophagy Regulation against Liver Fibrogenesis. Antioxidants, 12(2):493.
- Kishi et al. (2013). Liver Hydrolysate Assists in the Recovery From Physical Fatigue in a Mouse Model. Journal of Pharmacological Sciences. ScienceDirect.
- Kishi et al. (2020). A novel dipeptide derived from porcine liver hydrolysate induces recovery from physical fatigue in a mouse model. Journal of Functional Foods. ScienceDirect.
- Kaslow JE, Rucker L, Onishi R. (1989). Liver extract-folic acid-cyanocobalamin vs placebo for chronic fatigue syndrome. Archives of Internal Medicine, 149(11):2501–2503. PubMed ID: 2684076
- NIH Office of Dietary Supplements: Iron – Health Professional Fact Sheet
- Nguyen M, Tadi P. Dietary Iron. StatPearls. NCBI Bookshelf. NIH.
- Abbaspour et al. (2025). Dietary Heme Iron: A Review of Efficacy, Safety and Tolerability. Nutrients, 17(13):2132. PMC.
- Systematic review and meta-analysis: Heme vs. non-heme iron administration in randomized controlled trials. PMC11663168.
- Piskin et al. (2022). Iron Absorption: Factors, Limitations, and Improvement Methods. Journal of Soil Science and Plant Nutrition. PMC9219084.
- Piras et al. (2022). Occurrence of Toxic Metals and Metalloids in Muscle and Liver of Italian Heavy Pigs. Nutrients. PMC9407101.
- WebMD Natural Medicines: Liver Extract Overview, Uses, Side Effects, Dosing
- BIOFAC A/S: Liver Hydrolysate Product and Application Information
- Interventions for the treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis. PMC1743629.
Volver